Formosa Laboratories Sees Double Wins with Record May Revenue and Subsidiary’s IPO Approval

Taiwan Liposome Company (Formosa Laboratories), a leading CDMO and raw material pharmaceutical manufacturer, has reported impressive achievements this month. The company announced that its May revenue reached NT$455 million, marking a historical high for the same period and the third-highest monthly revenue on record. This represents a 41% month-over-month increase and a 38% year-over-year increase. Additionally, Formosa Laboratories’s subsidiary, Taiwan Liposome Company New Drug (Formosa Pharmaceuticals), has received approval from the Taiwan Stock Exchange for its IPO, pending board approval, with expectations to go public in the second half of the year.